BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Price, Quote, News and Overview
NASDAQ:BMRN - Nasdaq - US09061G1013 - Common Stock - Currency: USD
BMRN Quote, Performance and Key Statistics
58.01
-0.47 (-0.8%)
The current stock price of BMRN is 58.01 USD. In the past month the price decreased by -7.54%. In the past year, price decreased by -23.19%.
BMRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About BMRN
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,040 full-time employees. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia.
Company Info
BIOMARIN PHARMACEUTICAL INC
105 Digital Drive
Novato CALIFORNIA 94901 US
CEO: Jean-Jacques Bienaime
Employees: 3040
Phone: 14155056700
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
What is the stock price of BIOMARIN PHARMACEUTICAL INC today?
The current stock price of BMRN is 58.01 USD. The price decreased by -0.8% in the last trading session.
What is the ticker symbol for BIOMARIN PHARMACEUTICAL INC stock?
The exchange symbol of BIOMARIN PHARMACEUTICAL INC is BMRN and it is listed on the Nasdaq exchange.
On which exchange is BMRN stock listed?
BMRN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOMARIN PHARMACEUTICAL INC stock?
35 analysts have analysed BMRN and the average price target is 97.98 USD. This implies a price increase of 68.9% is expected in the next year compared to the current price of 58.01. Check the BIOMARIN PHARMACEUTICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOMARIN PHARMACEUTICAL INC worth?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a market capitalization of 11.12B USD. This makes BMRN a Large Cap stock.
How many employees does BIOMARIN PHARMACEUTICAL INC have?
BIOMARIN PHARMACEUTICAL INC (BMRN) currently has 3040 employees.
What are the support and resistance levels for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a resistance level at 63.31. Check the full technical report for a detailed analysis of BMRN support and resistance levels.
Is BIOMARIN PHARMACEUTICAL INC (BMRN) expected to grow?
The Revenue of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 11.4% in the next year. Check the estimates tab for more information on the BMRN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BMRN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BMRN, evaluating the profitability, health, valuation and growth aspects
- BIOMARIN PHARMACEUTICAL INC (BMRN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOMARIN PHARMACEUTICAL INC (BMRN) Sales and EPS estimates to see what analysts future expectations are.
- BIOMARIN PHARMACEUTICAL INC (BMRN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOMARIN PHARMACEUTICAL INC (BMRN) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Chart to make your own analysis
- BIOMARIN PHARMACEUTICAL INC (BMRN) Latest news and press-releases to stay up to date.
Does BIOMARIN PHARMACEUTICAL INC (BMRN) stock pay dividends?
BMRN does not pay a dividend.
When does BIOMARIN PHARMACEUTICAL INC (BMRN) report earnings?
BIOMARIN PHARMACEUTICAL INC (BMRN) will report earnings on 2025-08-04, after the market close.
What is the Price/Earnings (PE) ratio of BIOMARIN PHARMACEUTICAL INC (BMRN)?
The PE ratio for BIOMARIN PHARMACEUTICAL INC (BMRN) is 21.49. This is based on the reported non-GAAP earnings per share of 2.7 and the current share price of 58.01 USD. Check the full fundamental report for a full analysis of the valuation metrics for BMRN.
What is the Short Interest ratio of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The outstanding short interest for BIOMARIN PHARMACEUTICAL INC (BMRN) is 2.37% of its float. Check the ownership tab for more information on the BMRN short interest.
BMRN Technical Analysis
BMRN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BMRN. Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidiy or solvency issues.
BMRN Financial Highlights
Over the last trailing twelve months BMRN reported a non-GAAP Earnings per Share(EPS) of 2.7. The EPS increased by 136.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.76% | ||
| ROA | 7.33% | ||
| ROE | 9.04% | ||
| Debt/Equity | 0.1 |
BMRN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BMRN. The Buy consensus is the average rating of analysts ratings from 35 analysts.
For the next year, analysts expect an EPS growth of 56.4% and a revenue growth 11.4% for BMRN